Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2032-05-16 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Disposition to issuer · Disposed 36,806 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.94 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 11,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.30 · Expires 2034-05-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 8,011 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 9,174 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 16,675 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 26, 2026 21:44 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001628280-26-045841 · wk-form4_1782510295.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Stock · 19,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 9,174 | Not disclosed Strike: $63.68 | Not disclosed |
DisclosureSEC source: 0001663771-26-000002 · form4-04282026_080414.xml · derivative · entry 4 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,174 shares Expires 2035-05-29 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 8,011 | Not disclosed Strike: $51.30 | Not disclosed |
DisclosureSEC source: 0001663771-26-000002 · form4-04282026_080414.xml · derivative · entry 3 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,011 shares Expires 2034-05-28 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 11,459 | Not disclosed Strike: $37.94 | Not disclosed |
DisclosureSEC source: 0001663771-26-000002 · form4-04282026_080414.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,459 shares Expires 2033-06-14 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 36,806 | Not disclosed Strike: $7.61 | Not disclosed |
DisclosureSEC source: 0001663771-26-000002 · form4-04282026_080414.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,806 shares Expires 2032-05-16 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 21:41 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 14,750 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001437749-25-021366 · rdgdoc.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Class A Common Stock · 14,750 shares Expires 2035-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:14 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 9,174 | $0.00 Strike: $63.68 | $0.00 |
DisclosureSEC source: 0001415889-25-014986 · form4-05302025_080559.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 9,174 shares Expires 2035-05-29 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:56 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015354 · ownership.xml · nonDerivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:56 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 16,675 | $3.65 | $60,863.75 |
DisclosureSEC source: 0000950170-25-015354 · ownership.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| May 28, 2024 Filed Jun 6, 2024 20:18 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 8,011 | $0.00 Strike: $51.30 | $0.00 |
DisclosureSEC source: 0001415889-24-015745 · form4-06062024_080651.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,011 Underlying: Common Stock · 8,011 shares Expires 2034-05-28 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 28, 2025 or the next annual meeting of stockholders. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:55 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 3,700 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018621 · rdgdoc.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700 Underlying: Class A Common Stock · 3,700 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 23,458 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001479290-24-000090 · wk-form4_1714740469.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2034-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000090 · wk-form4_1714740469.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 9,402 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001415889-24-011120 · form4-04182024_080409.xml · derivative · entry 4 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,806 Underlying: Common Stock · 9,402 shares Expires 2032-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean May 16, 2022. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 2,612 | $56.03 | $146,352.97 |
DisclosureSEC source: 0001415889-24-011120 · form4-04182024_080409.xml · nonDerivative · entry 3 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023. F3 · price: Represents the weighted average share price of an aggregate total of 2,612 shares sold in the price range of $55.87 to $56.8699 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 6,790 | $55.36 | $375,906.62 |
DisclosureSEC source: 0001415889-24-011120 · form4-04182024_080409.xml · nonDerivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,612 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023. F2 · price: Represents the weighted average share price of an aggregate total of 6,790 shares sold in the price range of $54.87 to $55.8699 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 20:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 9,402 | $7.61 | $71,549.22 |
DisclosureSEC source: 0001415889-24-011120 · form4-04182024_080409.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 22:38 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001415889-24-008340 · form4-03182024_100301.xml · derivative · entry 5 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,208 Underlying: Common Stock · 9,000 shares Expires 2032-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean May 16, 2022. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 22:38 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 3,337 | $70.99 | $236,881.28 |
DisclosureSEC source: 0001415889-24-008340 · form4-03182024_100301.xml · nonDerivative · entry 4 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023. F4 · price: Represents the weighted average share price of an aggregate total of 3,337 shares sold in the price range of $70.84 to $71.8399 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 22:38 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 3,763 | $70.36 | $264,768.44 |
DisclosureSEC source: 0001415889-24-008340 · form4-03182024_100301.xml · nonDerivative · entry 3 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,337 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023. F3 · price: Represents the weighted average share price of an aggregate total of 3,763 shares sold in the price range of $69.83 to $70.8299 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 22:38 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,900 | $69.44 | $131,932.20 |
DisclosureSEC source: 0001415889-24-008340 · form4-03182024_100301.xml · nonDerivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,100 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023. F2 · price: Represents the weighted average share price of an aggregate total of 1,900 shares sold in the price range of $68.74 to $69.7399 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 22:38 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 9,000 | $7.61 | $68,490.00 |
DisclosureSEC source: 0001415889-24-008340 · form4-03182024_100301.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:23 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 11,459 | $0.00 Strike: $37.94 | $0.00 |
DisclosureSEC source: 0001209191-23-037854 · doc4.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,459 Underlying: Common Stock · 11,459 shares Expires 2033-06-14 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2024 or the next annual meeting of stockholders. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 5,915 | $0.00 Strike: $33.61 | $0.00 |
DisclosureSEC source: 0001479290-23-000063 · wf-form4_168332129959439.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,915 Underlying: Common Stock · 5,915 shares Expires 2033-05-02 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Ware's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000063 · wf-form4_168332129959439.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,675 F1 · acquired: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Ware's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 16, 2022 Filed May 17, 2022 21:14 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 55,208 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001209191-22-029759 · doc4.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,208 Underlying: Common Stock · 55,208 shares Expires 2032-05-16 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean May 16, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:17 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 11,343 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000058 · wf-form4_165187544365949.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 Underlying: Common Stock · 11,343 shares Expires 2032-05-03 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:17 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-22-000058 · wf-form4_165187544365949.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,141 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 04, 2022 Filed May 13, 2022 18:16 UTC Amendment | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 10,756 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000070 · wf-form4a_165248009386130.xml · derivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 Underlying: Common Stock · 10,756 shares Expires 2032-05-03 F1 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:23 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 1,268 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0001479290-21-000118 · wf-form4_162042978578360.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,268 Underlying: Common Stock · 1,268 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:23 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 674 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000118 · wf-form4_162042978578360.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,082 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:13 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 11,161 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001479290-21-000073 · wf-form4_161542161063629.xml · derivative · entry 2 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,161 Underlying: Common Stock · 11,161 shares Expires 2031-03-07 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary of the date of grant, March 8, 2022, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an initial grant pursuant to the Compensation Policy. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:13 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000073 · wf-form4_161542161063629.xml · nonDerivative · entry 1 Ware Olivia C · CIK 0001663771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,408 F1 · shares: Represents an initial restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary of the date of grant, March 8, 2022, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.